首页> 外文OA文献 >Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin

【2h】

Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin

机译：间接比较胰岛素的胰岛素肺胆碱/丽西酮和胰岛素Degludec /胰岛素Aspart在基础胰岛素上的2型糖尿病患者中的胰岛素Degludec /胰岛素Aspart

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Anwar Ali Jammah;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-na?ve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study [J] . Seiya Shimoda, Wakana Sakamoto, Ayaka Hokamura, Endocrine journal . 2019,第8期

机译：胰岛素-NA've日本成年人患有2型糖尿病的胰岛素-NA've日本成年人的疗效和安全性的疗效和安全性的疗效和安全性和胰岛素的疗效和安全性和胰岛素的疗效和安全性：飞行员，随机，受控研究
2. Efficacy and safety of switching from basal insulin to once‐daily insulin degludec/insulin aspart in Japanese patients with inadequately controlled type 2 diabetes: A 4‐week, randomized, open‐label, treat‐to‐target study [J] . Yoshio Nagai, Ami Nishine, Eriko Hashimoto, Journal of diabetes investigation. . 2018,第3期

机译：在基础性2型糖尿病控制不佳的日本患者中，从基础胰岛素转为每日一次胰岛素地德格雷/门冬胰岛素的疗效和安全性：一项为期4周，随机，开放标签，靶向治疗的研究
3. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN? Basal-Bolus Type 1): 2-year results of a randomized clinical trial [J] . BodeB.W., BuseJ.B., FisherM., Diabetic medicine: A journal of the British Diabetic Association . 2013,第11期

机译：在1型糖尿病（BEGIN？Basal-Bolus 1型）中，就餐时服用门冬胰岛素的基础大剂量治疗，胰岛素degludec可以比甘精胰岛素改善夜间血糖低的血糖控制风险：一项为期2年的随机临床试验结果
4. Switching to insulin glargine 300 U/mL from other basal insulin analogues provides less 24-hour glucose variability in hospitalized patients with type 1 diabetes [C] . V.V. Klimontov, E.A. Koroleva, O.N. Fazullina International Multiconference Bioinformatics of Genome Regulation and StructureSystems Biology . 2018

机译：从其他基础胰岛素类似物转换为甘精胰岛素300 U / mL可使住院的1型糖尿病患者的24小时葡萄糖变异性降低
5. Evaluating Hypoglycemic Risk of Two Basal Insulin Delivery Methods for Type 1 Diabetes: A Comparison of Tresiba Insulin Against Continuous Subcutaneous Insulin Infusion Using Data from Continuous Glucose Monitors [D] . Lane, Benjamin. 2020

机译：评估1型糖尿病两种基础胰岛素递送方法的低血糖风险：使用来自连续葡萄糖监测器的数据进行TRESIBA胰岛素对连续皮下胰岛素输注的比较
6. Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial [O] . Ajay Kumar, Edward Franek, Jonathan Wise, -1

机译：胰岛素初治的2型糖尿病患者每日一次胰岛素Degludec /门冬胰岛素与胰岛素甘草糖（U100）的疗效和安全性52周：一项随机对照试验
7. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin [O] . Marc Evans, Liana K. Billings, Jonas Håkan-Bloch, 2017

机译：间接治疗比较胰岛素Degludec / Liraglutide（IDEGLIRA）和胰岛素甘氨酸/ Lixisenatide（Iglarllixi）在基础胰岛素上不受控制的2型糖尿病患者中的疗效进行比较

Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin

著录项

相似文献

相关主题

期刊订阅